Articles tagged with Cancer Patients
Scientists at Sanford Burnham Prebys Medical Discovery Institute used publicly available cancer databases to identify novel cancer driver genes associated with cancer progression. The study found 71 previously unrecognized interfaces in proteins that may serve as new predictive markers or drug targets.
A multicomponent outreach program increased completion of the three-dose HPV vaccination series in adolescent girls, with mixed results by race/ethnicity. The study found that HPV vaccine-specific educational materials were effective for Hispanic parents, but not for African-American parents.
Three NIH-funded studies found that a genetic mutation linked to ALS and FTD impairs nuclear transport in neurons, leading to defects in gene expression. Researchers suggest therapies targeting nucleocytoplasmic transport may be effective in treating these diseases.
A team of scientists analyzed high-throughput sequencing data from 538 CLL patients and identified 44 genes that are frequently mutated in the disease. These mutations, known as driver mutations, affect RNA processing, MYC activity, and MAPK signaling.
Scientists have developed a blood test that can pair cancer patients with the most suitable therapy for their disease, giving real-time updates on tumor progression. This approach could make diagnosis, treatment, and monitoring quicker, cheaper, and less invasive.
Researchers have discovered a new gene, snoRNA42, linked to an increased risk of bowel cancer recurrence and shortened survival. This gene may serve as a reliable biomarker for selecting high-risk patients who can benefit from personalized treatments.
A new five-gene signature, MG5, identifies high-risk children with aggressive forms of the disease, suggesting personalized treatment options. The test has been validated in samples from 68 patients and could lead to improved survival rates and reduced side effects.
Scientists developed a test to identify patients at risk of relapse from non-seminomatous germ cell tumour. The test assessed three features: CXCL12 levels, cancer stem cells, and blood vessel presence. It divided patients into three risk groups, with the low-risk group experiencing high relapse-free survival rates.
A study found that a specific gene signature called MG5 can divide intermediate-risk rhabdomyosarcoma patients into two separate risk groups. Those with high MG5 scores had poorer survival outcomes and were seven times more likely to die of the disease.
A recent study by researchers at King's College London found that general practices using the urgent referral pathway (two-week wait system) have lower cancer mortality rates compared to those that rarely use this pathway. Increasing its use could improve patient survival, especially for patients from low-referring practices.
A study by Cancer Research UK and King's College London found that cancers diagnosed at a later stage have higher mortality rates, with death rates increasing by seven per cent in practices using the two-week referral route least often. Increasing GP cancer awareness could help reduce deaths.
Researchers identified four consensus molecular subtypes of bowel cancer, allowing doctors to treat each type differently. The study has implications for identifying patients at risk of developing more serious disease and tailoring treatments.
Researchers at Georgetown University Medical Center have discovered a compound that effectively controls the growth of EWS-FLI1-driven cancer cells in mice. The study found that YK-4-279 significantly reduced leukemia cell numbers and improved mouse health, suggesting potential as a therapeutic agent for various cancers.
A new study published in BMC Medicine found that dying at home is associated with a similar amount of pain compared to hospital deaths, and reduced grief for relatives. The study highlights the importance of access to comprehensive home care packages and facilitation of family caregiving.
A recent study published in JAMA Oncology examined cancer-care outcomes among US hospitals and found significant differences in long-term survival rates among four major categories of hospitals: PPS-exempt, NCI cancer centers, AMC, and other hospitals. The analysis revealed substantial gaps in survival rates, with patients treated at P...
Researchers discovered elephants have 38 additional modified copies of the p53 gene, which encodes a well-defined tumor suppressor. This unique genetic feature may protect elephants from cancer by enhancing their ability to kill damaged cells.
A recent study found that up to 90% of people in low-income countries lack radiotherapy treatment, leading to millions of deaths and lost economic benefits. Expanding access could save an estimated 26.9 million life-years by 2035.
Dan's House of Hope will receive the award to continue providing a place to live, programs, and home-away-from-home services for older adolescents and young adults with cancer. The organization helps reduce isolation, decrease financial burdens, and nourish hope for patients aged 15-39.
The ThriveWell Cancer Foundation will receive an $8,500 grant from the American Society for Radiation Oncology (ASTRO) to support its Patient Assistance Program. The program provides financial and transportation assistance to low-income cancer patients in San Antonio.
Researchers at DTU Systems Biology have developed a new diagnostic technology, TumorTracer, which identifies the source of cancer with 85% certainty. The method uses advanced self-learning computer algorithms to analyze DNA mutations in cancer tissue samples.
Researchers have discovered four unique metabolites in urine samples that can accurately distinguish between malignant and benign adrenal tumors. These biomarkers show high sensitivity (94.7%) and specificity (82.6%) for diagnosing cancer, potentially improving treatment decisions for patients with adrenal incidentalomas.
UT Southwestern researchers have developed a classification model for cancers caused by KRAS, the most frequently mutated gene in cancer. The model helps predict the propensity of different KRAS mutants to signal through RAF kinase and could lead to more effective targeted therapies.
Researchers describe a case of a 53-yr-old male with early T-cell precursor leukemia who achieved complete remission after treatment with the NOTCH inhibitor BMS-906024. Genetic and epigenetic analysis revealed that the patient's cancer was driven by hyperactive NOTCH1 signaling, which was successfully targeted by GSI treatment.
Two studies found that minimally invasive laparoscopic-assisted resection did not provide better cancer outcomes compared to open resection for patients with stage II or III rectal cancer. Laparoscopic resection was also shown to be inferior in terms of cancer control and adequacy of removal.
A randomized clinical trial published in JAMA found that laparoscopic surgery for rectal cancer has not yet been established as a routine procedure. The ALaCaRT trial showed similar success rates and fewer complications compared to open surgery, but with some concerns about margin involvement.
A genetic polymorphism in the EPAS1 gene has been associated with poor prognosis and enhanced expression in patients with non-small cell lung cancer. The study found that individuals with the A allele had a significantly shorter overall survival time compared to those with the G allele.
Cancer cases worldwide are projected to reach almost 22 million by 2030, with low- and middle-income countries facing unsustainable economic burdens. Effective cancer prevention campaigns have shown promising results in Taiwan, Rwanda, and Brazil, highlighting the importance of rapid implementation of control programs.
Researchers have discovered a new approach to understanding cancer mechanisms, biomarkers, and treatments using RNA editing events. The study, published in Cancer Cell, found that specific RNA editing processes could selectively affect drug sensitivity and may lead to the development of targeted therapies.
A Mayo Clinic study found that genetic differences among races affect colon cancer recurrence. Tumors from whites were twice as likely to have BRAF mutations, while black tumors had the highest frequency of KRAS mutations, leading to a higher risk of recurrence among young blacks.
KW-0761 efficiently eliminates Tregs from the blood of patients with lung or esophageal cancer, potentially augmenting the natural anticancer immune response. The study found a modest induction of antitumor immune responses and no marked clinical responses in patients treated with KW-0761 monotherapy.
A study of 47,000 patients found that nearly a third received more than 25 radiation treatments, despite guidelines recommending no more than 15. Privately insured patients were 40% more likely to be overtreated, highlighting the need for education and financial transparency.
The Lancet Oncology Commission highlights the vital role of primary care doctors in preventing, detecting, survivorship, and palliative care. Effective integration between primary and specialist care is crucial to meet the growing demand for cancer care.
The article explores eight big questions in cancer research, including the role of genetic mutations, tumor microenvironments, and epigenetics. Researchers discuss the importance of targeted treatments, prevention, and screening, as well as the potential for precision medicine to improve cancer outcomes.
A major new Commission reveals that over three-quarters of people with cancer worldwide have no access to safe surgery, with the global economy facing potential losses of over $6 trillion by 2030. The shortage is worst in low-income countries, where as many as 95% of people with cancer do not receive basic cancer surgery.
Cancer patients with high cardiovascular hormone/peptide levels have a shorter survival rate, even without clinical signs of heart disease or infection. These biomarkers indicate heart tissue damage directly linked to cancer progression.
The CheckMate 057 trial shows that nivolumab improves overall and 12-month survival rates compared to docetaxel in non-squamous non-small cell lung cancer patients. Nivolumab also demonstrated better patient-reported outcomes, including quality of life and slower disease deterioration.
A large study found that aspirin use after a cancer diagnosis significantly increases overall survival rates for patients with gastrointestinal tumours. The researchers analysed data from nearly 14,000 patients and discovered a strong association between aspirin use and improved survival.
A phase III trial has shown that 177Lu-DOTATATE significantly improves progression-free survival in patients with mid-gut neuroendocrine tumours, a rare and hard-to-treat disease. The treatment outperforms standard care in terms of time without disease progression.
Research highlights significant disparities in cancer care among migrants and refugees, with lower rates of early diagnosis and treatment. The European Society for Medical Oncology calls for policy changes to address these disparities and improve access to quality cancer care.
Researchers found molecular differences in younger-onset CRC tumors related to epigenetics and gene expression. This discovery could lead to tailored treatments for younger patients. The study analyzed genetic mutations in 126 under-50 patients and 368 over-50 patients, revealing distinctive patterns.
A global shortfall in radiotherapy resources has led to millions of unnecessary deaths, but investing in radiotherapy services could bring economic benefits of up to $365 billion over the next 20 years. Access to radiotherapy is currently unacceptably low, especially in Africa, where most countries have no facilities.
Patients with advanced throat cancer who underwent primary surgery had significantly higher overall survival rates compared to those who did not. The study found that radical surgery improved survival in both oropharyngeal and hypopharyngeal cancers, with notable benefits for patients with stage III and IVa disease.
The EUROCARE 5 study shows significant geographical variations in survival from blood cancers in Europe, with the highest five-year relative survival rate for Hodgkin lymphoma at 81% in Northern European countries. In contrast, chronic myeloid leukemia had a significantly lower survival rate of 53%, particularly in Eastern Europe.
The CheckMate 025 phase III clinical trial shows that nivolumab significantly prolongs survival in patients with advanced kidney cancer, regardless of PD-L1 expression. The study found a median overall survival of 25 months for nivolumab-treated patients compared to 19.6 months for those treated with everolimus.
Individualized medicine is revolutionizing patient care through precision diagnostics, such as preventing drug-related adverse effects and identifying disease susceptibility. Whole exome sequencing is also offering new diagnoses for patients with undiagnosed diseases.
Researchers suggest that combining epigenetic therapies with immunotherapies could restore cell-surface molecules that help the immune system eliminate cancer cells. Epigenetic drugs can also lower or eliminate immune cells that facilitate tumor growth.
A new study identifies USP19 as a potential drug target for muscle wasting diseases in cancer patients, improving quality of life and longevity. The research team discovered that inhibiting the USP19 gene could protect against muscle wasting in mice models.
A new study reveals that social factors such as insurance status, marital status, and county-level income significantly affect the chances of survival in young patients with acute myelogenous leukemia (AML). The findings highlight the need to address these non-biological patient characteristics to improve health outcomes.
A new study shows that a small implantable device can attract and capture malignant cells in breast cancer patients, potentially giving doctors earlier warnings of relapse. The device exploits the natural attraction of cancer cells to specific areas of the body, slowing down their spread to other organs.
Researchers discovered that Tie1 controls angiogenesis and vascular remodeling by differentially regulating Tie2 in tip and stalk cells, making it a promising therapeutic target for cancer treatment and eye diseases.
A multiple myeloma patient experienced complete remission after receiving a personalized cellular therapy called CTL019, which targets cancerous white blood cells. The treatment was combined with chemotherapy and an autologous stem cell transplant, and the patient remains in remission over 12 months after infusion.
Researchers found that microRNA 506 acts as a tumor suppressor in gastric cancer, inhibiting angiogenesis and metastasis. Patients with high miR-506 expression have significantly longer survival times compared to those with low expression levels.
Researchers at Baylor College of Medicine have discovered a new way to kill cancers driven by the MYC gene, which is responsible for aggressive behavior in many types of malignancies. By inhibiting the spliceosome, a complex machine within cancer cells, scientists can target and destroy tumor cells without harming normal tissues.
The use of contralateral prophylactic mastectomy (CPM) among US men with breast cancer has increased significantly, rising from 3% to 5.6% between 2004 and 2011. The procedure was more common in younger, white, and privately insured patients.
A study published in JAMA found that incorporating genomic sequencing and counseling into pediatric cancer treatment improved patient outcomes and changed treatment plans. The study showed that nearly half of patients had actionable findings that led to individualized actions, including genetic counseling and changes in treatment.
A new study found that using a patient's entire genome helped suggest personalized treatment options for nearly half of children with cancer. The approach led to specific treatment changes in a quarter of these patients and showed promise in treating difficult-to-treat cancers.
Researchers found that MACC1 expression is a key indicator of survival and recurrence risk in Klatskin carcinoma patients. Patients with low MACC1 levels have a good chance of benefiting from surgery, while those with high levels are at a higher risk of cancer recurrence.
Researchers at Ohio State University Comprehensive Cancer Center have designed an online database called CanDL to help molecular pathologists identify key cancer gene mutations. The freely accessible database includes information on 60 genes, 334 distinct variants and 169 unique matching literature references across multiple cancers.
Researchers have developed a blood test that can identify patients at risk of breast cancer relapse months before visible signs appear. The test detects cancer DNA in the bloodstream, allowing for early intervention and personalized treatment.
A Veterans Affairs team found that longer-lasting colonoscopies are associated with lower cancer rates. Doctors with average withdrawal times of under six minutes had patients more than twice as likely to have cancer. Experts recommend focusing quality-improvement efforts on withdrawal times of under six minutes.